Overview
Tesamorelin is a synthetic polypeptide composed of 44 amino acids and is being developed as an analog of the natural growth hormone-releasing hormone (GHRH). Targeted chemical modifications at both the N-terminus and C-terminus make Tesamorelin different from natural GHRH. Researchers suspect that these modifications contribute to increased stability and improved resistance to enzymatic degradation.
How does Tesamorelin work, according to research?
The proposed mechanism of action of Tesamorelin is very similar to that of natural GHRH. In research models, the peptide may bind to GHRH receptors in the anterior pituitary gland, which can lead to increased production and release of growth hormone (hGH).
Growth hormone plays a key role in various physiological processes. Among other things, it can act on liver cells (hepatocytes), where it stimulates the production of insulin-like growth factor-1 (IGF-1). In addition, growth hormone can also locally promote IGF-1 production in other tissues.
IGF-1 is considered the most important anabolic mediator of growth hormone and is associated with cell growth and the inhibition of programmed cell death. Growth hormone itself, on the other hand, is primarily associated with lipolytic effects, stimulating fat breakdown in specific fat depots, such as visceral and abdominal fat.
Tesamorelin and Lipodystrophy
Lipodystrophy is characterized by abnormal fat distribution, with fat loss in some areas (lipoatrophy) and accumulation in others (lipohypertrophy). This condition is often accompanied by metabolic disturbances such as insulin resistance and elevated triglyceride and cholesterol levels.
Tesamorelin was studied for 26 weeks in two phase III studies involving a total of 806 subjects with lipodystrophy. The results showed a significant reduction in visceral adipose tissue, with an average reduction of at least 15.4%. Triglyceride and cholesterol levels were also lower than in the placebo group.
Tesamorelin and Cognitive Function
An ongoing clinical trial is investigating the potential effect of Tesamorelin on cognitive function in immunodeficient models with mild cognitive impairment. One hundred subjects over 40 years of age were administered Tesamorelin over multiple study phases.
The primary outcome is change in neurocognitive performance, measured by the Global Deficit Score (GDS). Final results have not yet been published.
Tesamorelin and Muscle Tissue
A study using CT scans examined changes in muscle quality and volume. The results suggested a possible increase in muscle density and size, particularly in the rectus abdominis, psoas major, and paravertebral muscles. These changes were statistically significant compared to the placebo group.
Tesamorelin and Visceral Fat
Visceral obesity, often associated with lipodystrophy, is linked to metabolic disorders such as insulin resistance, elevated LDL cholesterol, and atherosclerosis. Research on tesamorelin shows that the peptide can contribute to a reduction in visceral fat by up to 25% in certain research models.
Buy Tesamorelin for research
For researchers seeking high-quality Tesamorelin for laboratory studies, Biomedics Lab offers only carefully lab-tested research peptides. Our products meet strict quality standards and are intended solely for research use.
